Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gepotidacin penetration into prostate and tonsillar tissue
2019-004308-37Phase 2Completed
- Sponsor
- Inserm
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gepotidacin, sponsored by Inserm. Primary endpoint: Tissue pharmacokinetic parameters. Started Jul 2020; status: completed.
02
Drugs
gepotidacin
Beyond the preview
Go deeper on 2019-004308-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004308-37.